Posts

Mechanistic insights supporting the sufficiency and inventive step of a therapeutic use (without clinical data) (T 1601/22)

Sufficiency at the priority date: A study protocol is not "the same" as a therapeutic effect invention (T0883/23)

When your formulation IP is beyond compare (T 0722/24)

The criteria for the novelty and inventive step of pharmaceutical selection inventions (T 1356/21)

Second medical use dosage regimen claim successfully traverses both insufficiency and "obvious-to-try" attacks (T 0799/16)

Canadian Federal Court considers whether Teva's COPAXONE second medical use patents were obvious-to-try (Teva v Pharmascience)

The English approach to obviousness - It all depends on the facts?

Mr Justice Carr tackles plausibility in Actavis v Eli Lilly ADHD dispute (Part II)